Open AccessImproved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases
Author(s) -
Michael Zhang,
Adrian Rodrigues,
Erqi L. Pollom,
Iris C. Gibbs,
Scott G. Soltys,
Steven Hancock,
Joel W. Neal,
Sukhmani K. Padda,
Kavitha Ramchandran,
Heather A. Wakelee,
Steven D. Chang,
Michael Lim,
Melanie Hayden Gephart,
Gordon Li
Publication year - 2021
Publication title -
journal of neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.256
H-Index - 114
eISSN - 1573-7373
pISSN - 0167-594X
DOI - 10.1007/s11060-020-03686-3
Subject(s) - pembrolizumab , medicine , brain metastasis , lung cancer , oncology , adverse effect , hazard ratio , cancer , immunotherapy , metastasis , confidence interval
Immune checkpoint inhibitors have become standard of care for many patients with non-small cell lung cancer (NSCLC). These agents often cause immune-related adverse events (IRAEs), which have been associated with increased overall survival (OS). Intracranial disease control and OS for patients experiencing IRAEs with metastatic NSCLC and brain metastases have not yet been described.